GEMoaB Announces First Patient Apheresed in a Phase IA Study with Lead Product Candidate from Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias


Dresden, Germany, 09 March 2020. GEMoaB, a biopharmaceutical company focused on the development of next generation immunotherapies for hard-to-treat cancers, today announced that it has apheresed the first patient in a Phase IA study with UniCAR-T-CD123, the lead product candidate from its proprietary UniCAR cellular immunotherapy platform. UniCAR has been designed to ensure excellent control […]